Etentamig

A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused ABBV-383 in Combination With Anti-Cancer Regimens for the Treatment of Adult Participants With Relapsed/Refractory Multiple Myeloma

Near Add Your Location

Sorting 21 by

Memorial Sloan Kettering Cancer Center
New York, NY
Fully Open
  • Not currently accepting
  • Show Principal Investigator
Moffitt Cancer Center
Magnolia Campus
Tampa, FL
  • Accepting patients
The University of Texas Southwestern Medical Center
Harold C. Simmons Comprehensive Cancer Center
Dallas, TX
  • Accepting patients
Huntsman Cancer Institute
University of Utah
Salt Lake City, UT
  • Accepting patients
Sylvester Comprehensive Cancer Center (Main)
University of Miami Health System
Miami, FL
  • Accepting patients

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print Report

Print a patient-friendly report to share with your patient.

(888) 850-0650

We can help answer any questions and connect you (or your patient) with the study team.

Schedule Call

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.